Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Toi

Showing results (181-190 of 199) with videos related to

Pageof 20
Sort By:
Breast Cancer Research and Treatment|June 13, 2012
Predictions of the pathological response to neoadjuvant chemotherapy in patients with primary breast cancer using a data mining techniqueM Takada, M Sugimoto, S Ohno, et al.
Asia-Pacific Journal of Clinical Oncology|April 4, 2017
Toxicity profile differences of adjuvant docetaxel/cyclophosphamide (TC) between Asian and Caucasian breast cancer patientsL W C Chow, L Biganzoli, A D Leo, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|June 15, 2016
Clinical benefit of nomogram for predicting positive resection margins in breast conserving surgeryE-S Lee, W Han, H-C Shin, et al.
British Journal of Cancer|October 22, 2009
Lapatinib monotherapy in patients with relapsed, advanced, or metastatic breast cancer: efficacy, safety, and biomarker results from Japanese patients phase II studiesM Toi, H Iwata, Y Fujiwara, et al.
Scientific Reports|February 8, 2017
Visualization of tumor-related blood vessels in human breast by photoacoustic imaging system with a hemispherical detector arrayM Toi, Y Asao, Y Matsumoto, et al.
Breast Cancer Research and Treatment|March 25, 2017
Outcomes of fulvestrant therapy among japanese women with advanced breast cancer: a retrospective multicenter cohort study (JBCRG-C06; Safari)H Kawaguchi, N Masuda, T Nakayama, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 21, 2016
Final efficacy and updated safety results of the randomized phase III BEATRICE trial evaluating adjuvant bevacizumab-containing therapy in triple-negative early breast cancerR Bell, J Brown, M Parmar, et al.
Breast Cancer Research and Treatment|October 15, 2013
Randomized trial of preoperative docetaxel with or without capecitabine after 4 cycles of 5-fluorouracil– epirubicin–cyclophosphamide (FEC) in early-stage breast cancer: exploratory analyses identify Ki67 as a predictive biomarker for response to neoadjuvant chemotherapyS Ohno, L W C Chow, N Sato, et al.
Breast Cancer Research and Treatment|April 1, 2014
Survival of HER2-positive primary breast cancer patients treated by neoadjuvant chemotherapy plus trastuzumab: a multicenter retrospective observational study (JBCRG-C03 study)M Takada, H Ishiguro, S Nagai, et al.
The Pharmacogenomics Journal|August 9, 2017
Characterisation of the HLA-DRB1*07:01 biomarker for lapatinib-induced liver toxicity during treatment of early-stage breast cancer patients with lapatinib in combination with trastuzumab and/or taxanesC F Spraggs, L R Parham, L P Briley, et al.
Pageof 20

Showing results (181-190 of 199) with videos related to

Sort By:
Pageof 20
Breast Cancer Research and Treatment|June 13, 2012
Predictions of the pathological response to neoadjuvant chemotherapy in patients with primary breast cancer using a data mining techniqueM Takada, M Sugimoto, S Ohno, et al.
Asia-Pacific Journal of Clinical Oncology|April 4, 2017
Toxicity profile differences of adjuvant docetaxel/cyclophosphamide (TC) between Asian and Caucasian breast cancer patientsL W C Chow, L Biganzoli, A D Leo, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|June 15, 2016
Clinical benefit of nomogram for predicting positive resection margins in breast conserving surgeryE-S Lee, W Han, H-C Shin, et al.
British Journal of Cancer|October 22, 2009
Lapatinib monotherapy in patients with relapsed, advanced, or metastatic breast cancer: efficacy, safety, and biomarker results from Japanese patients phase II studiesM Toi, H Iwata, Y Fujiwara, et al.
Scientific Reports|February 8, 2017
Visualization of tumor-related blood vessels in human breast by photoacoustic imaging system with a hemispherical detector arrayM Toi, Y Asao, Y Matsumoto, et al.
Breast Cancer Research and Treatment|March 25, 2017
Outcomes of fulvestrant therapy among japanese women with advanced breast cancer: a retrospective multicenter cohort study (JBCRG-C06; Safari)H Kawaguchi, N Masuda, T Nakayama, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 21, 2016
Final efficacy and updated safety results of the randomized phase III BEATRICE trial evaluating adjuvant bevacizumab-containing therapy in triple-negative early breast cancerR Bell, J Brown, M Parmar, et al.
Breast Cancer Research and Treatment|October 15, 2013
Randomized trial of preoperative docetaxel with or without capecitabine after 4 cycles of 5-fluorouracil– epirubicin–cyclophosphamide (FEC) in early-stage breast cancer: exploratory analyses identify Ki67 as a predictive biomarker for response to neoadjuvant chemotherapyS Ohno, L W C Chow, N Sato, et al.
Breast Cancer Research and Treatment|April 1, 2014
Survival of HER2-positive primary breast cancer patients treated by neoadjuvant chemotherapy plus trastuzumab: a multicenter retrospective observational study (JBCRG-C03 study)M Takada, H Ishiguro, S Nagai, et al.
The Pharmacogenomics Journal|August 9, 2017
Characterisation of the HLA-DRB1*07:01 biomarker for lapatinib-induced liver toxicity during treatment of early-stage breast cancer patients with lapatinib in combination with trastuzumab and/or taxanesC F Spraggs, L R Parham, L P Briley, et al.
Pageof 20